Controversy Surrounds UniQure's Huntington's Disease Gene Therapy

The U.S. Food and Drug Administration (FDA) has called for UniQure N.V. to conduct a new placebo-controlled trial for its gene therapy, AMT-130, aimed at treating Huntington's disease. A senior FDA official characterized the current treatment as a "failed product," asserting that previous trials did not adequately demonstrate its efficacy. The official emphasized that the agency has historically required randomized, placebo-controlled studies for Huntington's therapies, stating, “We have a failed product here,” and criticized UniQure for presenting "distorted or manipulated" data in its previous trials.

BenzingaReutersFierce BiotechCNBCFierce BiotechBioSpace

UniQure has expressed significant ethical concerns regarding the FDA's request for a sham surgery-controlled trial. The company's Chief Medical Officer, Walid Abi-Saab, argued that the proposed trial design would require patients to undergo general anesthesia and potentially face irreversible neurodegeneration during the control period. He stated, “Potentially at the end of this period, they might have progressed enough that they cannot benefit from the drug.” This sentiment was echoed by patient advocacy groups, including the Huntington's Disease Society of America, which warned that a two-year control period could severely impact patients' quality of life.

Fierce Biotech

The FDA's insistence on a placebo-controlled trial has sparked a contentious debate between the agency and UniQure. The FDA official clarified that the agency's request involved a small scalp incision rather than a more invasive procedure, countering UniQure's claims of a "sham surgery." The official stated, “We did not ask them to compare against a partial sham burr hole,” reinforcing the FDA's long-standing policy on trial designs for Huntington's therapies.

Fierce BiotechBenzingaFierce BiotechReutersCNBCBioSpace

Following the FDA's rejection of UniQure's data package, the company's stock experienced volatility, initially plummeting by 40% before recovering slightly. As of the latest reports, shares were trading around $10.75. The ongoing dispute has led to legal scrutiny, with firms like Portnoy Law Firm filing class-action suits against UniQure for alleged misleading statements regarding its trial design and communications with the FDA.

Benzinga

The FDA has defended its position, asserting that the request for a new trial is consistent with its regulatory framework for Huntington's disease therapies. The agency's official noted, “We only ask for randomized data when... the possibility you are fooling yourself is high.” Meanwhile, UniQure has indicated its willingness to work with the FDA to find a mutually acceptable path forward.

Benzinga

Critics of the FDA's approach, including medical professionals and patient advocates, have voiced concerns about the ethical implications of prolonged placebo-controlled trials for patients with rapidly progressing diseases. Testimonies from recent congressional hearings highlighted the potential risks of such trial designs, with experts arguing that they may lack compassion and ethical consideration for vulnerable patient populations.

Fierce Biotech

There remains a significant discrepancy between UniQure's portrayal of the FDA's requests and the agency's official statements. While UniQure claims that the FDA has shifted its stance on trial requirements, the FDA maintains that its expectations have been consistent. This ongoing conflict underscores the complexities of regulatory approval processes for innovative treatments in rare diseases.

Benzinga

• “was stone cold negative. We have a failed product here.” — Senior FDA Official

Reuters

• “Potentially at the end of this period, they might have progressed enough that they cannot benefit from the drug or they will never really get back” — Walid Abi-Saab, Chief Medical Officer, UniQure

Fierce Biotech

• “For Huntington's patients, a two-year period spent in a control arm of a study "is not a 'neutral' observation window, it is a period of active, irreversible neurodegeneration," the group said.” — Huntington's Disease Society of America

Reuters